Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. (Q34778011)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q52026452)
(Q21005392)
(Q51913713)
(Q102376697)
(Q87657745)
(Q104696550)
(P304) 522; discussion 522
(P407) (Q1860)
(P433) 7388
(P478) 326
(P577) Saturday, March 1, 2003
(P921) (Q8277)
(Q1754768)
(P1433) (Q546003)
(P1476) "Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis" (language: en)
(P2093) Chris McCabe
Nicola J Cooper
Cost Effectiveness of Multiple Sclerosis Therapies Study Group
(P2860) (Q34648776)
(Q50665932)
(Q34048580)
(Q33692026)
(Q34375520)
(Q28293763)
(Q22241644)
(Q28284428)
(Q53398786)
(Q52722694)
(Q71899123)
(Q69788749)
(Q74528524)
(Q77573167)
(Q77573170)
other details
description scientific article

External Links